Juno Therapeutics soars in Nasdaq debut
December 19, 2014 at 12:13 PM EST
CEO Hans Bishop told CNBC investors are feeling optimistic about immunotherapy and the company's cancer treatments in development.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.